摘要目的 探讨放射性核素131Ⅰ治疗甲状腺功能亢进的效果与安全性.方法 选取阳泉市第一人民医院2016年4月至2017年9月收治的甲状腺功能亢进患者96例,按双盲法分为两组,每组48例.对照组采用甲巯咪唑片治疗,试验组在此基础上采用放射性核素131Ⅰ治疗,两组均连续治疗6个月.比较两组患者的临床疗效、甲状腺功能及不良反应发生情况.结果 治疗后,试验组总有效率(93.75％)高于对照组(79.17％),差异有统计学意义(P<0.05).两组游离甲状腺素(FT4)、游离三碘甲状腺原氨酸(FT3)水平均低于治疗前,促甲状腺激素(TSH)水平高于治疗前,且试验组FT4、FT3水平均低于对照组,TSH水平高于对照组,差异有统计学意义(P<0.05).对照组不良反应发生率为18.75％,试验组为14.58％,两组比较差异未见统计学意义(P>0.05).结论 放射性核素131Ⅰ可改善甲状腺功能亢进患者的治疗效果,改善甲状腺功能,且未增加不良反应,安全性较高.

abstractsObjective To investigate the efficacy and safety of radionuclide 131Ⅰin the treatment of hyperthyroidism.Methods A total of 96 patients with hyperthyroidism in Yangquan First People 's Hospital from April 2016 to September 2017 were selected and divided into two groups by double -blind method, with 48 patients in each group.The control group was treated with methimazole tablets , while the experimental group was treated with radionuclide 131 Ⅰbased on methimazole tablets.After 6 months of continuous treatment, the clinical efficacy, thyroid function and adverse reactions of the two groups were compared.Results After treatment, the total effective rate of the experimental group was 93.75％, higher than the 79.17％ of the control group, with significant difference (P <0.05).The levels of free thyroxine (FT4) and free triiodothyroxine (FT3) in both groups were lower after treatment, on the contrary, and the levels of thyrotropin (TSH) were higher after treatment (P <0.05).The levels of FT4 and FT3 in the experimental group were lower than those in the control group , but the levels of TSH were higher, and the difference was statistically significant (P <0.05).The incidence of adverse reactions was 18.75％ in the control group, and 14.58％ in the experimental group, there was no significant difference between the two groups (P >0.05).Conclusions Radionuclide 131Ⅰcan improve the therapeutic effects of hyperthyroidism and thyroid function , without increase in incidence of adverse reactions, so it is safer.